European Commission approves a new 7.2 mg once weekly maintenance dose of Wegovy for obesity treatment in adults. The higher Wegovy dose expands Novo Nordisk's CPSE:NOVO B obesity treatment options ...

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults ...

Novo Nordisk NVO announced that the European Commission (EC) has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity. This provides physicians ...

Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. Click ...

John Flanagan, PhD, presented new research at WVC 2026 that shows that a purpose-formulated, low-digestible carbohydrate diet combined with structured caloric restriction substantially increases short ...

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out.

Research and Development (R&D) expenses: R&D expenses totaled $44.6 million for the fourth quarter of 2025 and $50.5 million ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M ...

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s ...

According to a new study, vadadustat was shown to be noninferior to darbepoetin alfa for both cardiovascular safety and ...